Total Payments
$2,902
2024 Payments
$185.37
Companies
10
Transactions
26
Medicare Patients
903
Medicare Billing
$112,808
Payment Breakdown by Category
Research$2,357 (81.2%)
Food & Beverage$544.40 (18.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,357 | 3 | 81.2% |
| Food and Beverage | $544.40 | 23 | 18.8% |
Payments by Type
Research
$2,357
3 transactions
General
$544.40
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $1,232 | 1 | $0 (2018) |
| Eli Lilly and Company | $1,125 | 2 | $0 (2018) |
| Sumitomo Pharma America, Inc. | $199.61 | 9 | $0 (2024) |
| ARRAY BIOPHARMA INC | $148.69 | 8 | $0 (2023) |
| The Medicines Company | $103.06 | 1 | $0 (2017) |
| Dexcom, Inc. | $25.15 | 1 | $0 (2024) |
| Medtronic USA, Inc. | $22.72 | 1 | $0 (2019) |
| EISAI INC. | $19.14 | 1 | $0 (2019) |
| AbbVie Inc. | $13.05 | 1 | $0 (2021) |
| Lilly USA, LLC | $12.98 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $185.37 | 8 | Sumitomo Pharma America, Inc. ($160.22) |
| 2023 | $81.72 | 4 | ARRAY BIOPHARMA INC ($42.33) |
| 2022 | $106.36 | 6 | ARRAY BIOPHARMA INC ($106.36) |
| 2021 | $13.05 | 1 | AbbVie Inc. ($13.05) |
| 2019 | $54.84 | 3 | Medtronic USA, Inc. ($22.72) |
| 2018 | $2,357 | 3 | NOVARTIS PHARMACEUTICALS CORPORATION ($1,232) |
| 2017 | $103.06 | 1 | The Medicines Company ($103.06) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $25.15 | General |
| Category: Endocrinology | ||||||
| 08/19/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $28.32 | General |
| Category: UROLOGY | ||||||
| 07/26/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $25.49 | General |
| Category: UROLOGY | ||||||
| 06/14/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: UROLOGY | ||||||
| 05/13/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: UROLOGY | ||||||
| 04/22/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: UROLOGY | ||||||
| 03/11/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $12.84 | General |
| Category: UROLOGY | ||||||
| 02/05/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $24.42 | General |
| Category: UROLOGY | ||||||
| 09/18/2023 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $23.95 | General |
| Category: Urology | ||||||
| 08/14/2023 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $15.44 | General |
| Category: Urology | ||||||
| 05/23/2023 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $22.47 | General |
| Category: ONCOLOGY | ||||||
| 03/07/2023 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $19.68 | General |
| Category: ONCOLOGY | ||||||
| 11/30/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $13.48 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $22.96 | General |
| Category: ONCOLOGY | ||||||
| 09/28/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: ONCOLOGY | ||||||
| 07/28/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: ONCOLOGY | ||||||
| 10/13/2021 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/06/2019 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $12.98 | General |
| Category: Neuroscience | ||||||
| 06/07/2019 | Medtronic USA, Inc. | INTELLIS (Device) | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 01/16/2019 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $19.14 | General |
| Category: Oncology | ||||||
| 07/12/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $375.00 | Research |
| Study: A SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LY3375880 IN HEALTHY SUBJECTS | ||||||
| 02/22/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | ZPL389A (Drug) | — | Cash or cash equivalent | $1,232.14 | Research |
| Study: A MULTI PART STUDY OF ZPL389 A HISTAMINE H4 RECEPTOR ANTAGONIST CONSISTING OF RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED SINGLE AND MULTIPLE ASCENDING ORAL DOSE STUDY PARTS TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS IN HEALTHY JAPANESE AND NON JAPANESE VOLUNTEERS AND AN OPEN LABEL FOOD EFFECTS STUDY PART IN HEALTHY VOLUNTEERS NONJAPANESE | ||||||
| 02/22/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $750.00 | Research |
| Study: SINGLE-DOSE, DOSE-ESCALATION STUDY WITH LY3303560 TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS IN HEALTHY SUBJECTS AND PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMERS DISEASE OR MILD TO MODERATE ALZHEIMERS DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTI PART STUDY OF ZPL389 A HISTAMINE H4 RECEPTOR ANTAGONIST CONSISTING OF RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED SINGLE AND MULTIPLE ASCENDING ORAL DOSE STUDY PARTS TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS IN HEALTHY JAPANESE AND NON JAPANESE VOLUNTEERS AND AN OPEN LABEL FOOD EFFECTS STUDY PART IN HEALTHY VOLUNTEERS NONJAPANESE | NOVARTIS PHARMACEUTICALS CORPORATION | $1,232 | 1 |
| SINGLE-DOSE, DOSE-ESCALATION STUDY WITH LY3303560 TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS IN HEALTHY SUBJECTS AND PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMERS DISEASE OR MILD TO MODERATE ALZHEIMERS DISEASE | Eli Lilly and Company | $750.00 | 1 |
| A SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LY3375880 IN HEALTHY SUBJECTS | Eli Lilly and Company | $375.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 378 | 514 | $126,899 | $46,638 |
| 2022 | 8 | 289 | 388 | $92,435 | $33,120 |
| 2021 | 6 | 166 | 228 | $61,048 | $22,160 |
| 2020 | 2 | 70 | 125 | $30,611 | $10,891 |
Total Patients
903
Total Services
1,255
Medicare Billing
$112,808
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 124 | 248 | $74,648 | $23,601 | 31.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 71 | 71 | $18,531 | $9,966 | 53.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 21 | $8,463 | $3,031 | 35.8% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 34 | 34 | $4,624 | $2,442 | 52.8% |
| 91322 | Sarscov2 vac 50 mcg/0.5ml im | Office | 2023 | 17 | 17 | $4,964 | $2,431 | 49.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 27 | 30 | $6,120 | $1,647 | 26.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 12 | $5,532 | $1,525 | 27.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 34 | 34 | $2,040 | $1,136 | 55.7% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 14 | 14 | $1,120 | $623.70 | 55.7% |
| 83037 | Hemoglobin a1c level, by device for home use | Office | 2023 | 12 | 20 | $740.00 | $190.40 | 25.7% |
| 81002 | Urinalysis, manual test | Office | 2023 | 13 | 13 | $117.00 | $44.33 | 37.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 94 | 182 | $54,782 | $16,679 | 30.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 52 | 52 | $13,572 | $7,603 | 56.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 30 | 39 | $7,956 | $2,934 | 36.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 31 | 31 | $4,216 | $2,046 | 48.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 17 | 17 | $7,837 | $1,757 | 22.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 30 | 30 | $1,800 | $1,012 | 56.2% |
| 0124A | Fee covid-19 vac 13 res | Office | 2022 | 21 | 21 | $1,680 | $935.76 | 55.7% |
| 83037 | Hemoglobin a1c level, by device for home use | Office | 2022 | 14 | 16 | $592.00 | $152.88 | 25.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 68 | 128 | $37,938 | $12,773 | 33.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 36 | 36 | $9,396 | $5,325 | 56.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 22 | 24 | $4,858 | $1,703 | 35.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 14 | 14 | $6,258 | $1,259 | 20.1% |
| 90662 | Vaccine for influenza for injection into muscle, split virus, preservation free | Office | 2021 | 13 | 13 | $1,818 | $848.38 | 46.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 13 | 13 | $780.00 | $251.68 | 32.3% |
About Dr. Stephen Yu, M.D
Dr. Stephen Yu, M.D is a Family Medicine healthcare provider based in Glendale, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/23/2016. The National Provider Identifier (NPI) number assigned to this provider is 1295284834.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Yu, M.D has received a total of $2,902 in payments from pharmaceutical and medical device companies, with $185.37 received in 2024. These payments were reported across 26 transactions from 10 companies. The most common payment nature is "" ($2,357).
As a Medicare-enrolled provider, Yu has provided services to 903 Medicare beneficiaries, totaling 1,255 services with total Medicare billing of $112,808. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Glendale, CA
- Active Since 09/23/2016
- Last Updated 06/18/2018
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1295284834
Products in Payments
- ZPL389A (Drug) $1,232
- GEMTESA (Drug) $199.61
- BRAFTOVI (Drug) $106.36
- ORBACTIV (Drug) $103.06
- LORBRENA (Drug) $42.33
- Dexcom G6 Transmitter (Medical Supply) $25.15
- INTELLIS (Device) $22.72
- Lenvima (Drug) $19.14
- LINZESS (Drug) $13.05
- EMGALITY (Drug) $12.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Glendale
Esther Yoon, M.d, M.D
Family Medicine — Payments: $1.1M
Family Medicine $1.1M
Dr. David Han, M.d, M.D
Family Medicine — Payments: $148,437
Family Medicine $148,437
Dr. Narine Arutyounian, M.d, M.D
Family Medicine — Payments: $110,426
Family Medicine $110,426
Dr. Rachel Langland, M.d, M.D
Family Medicine — Payments: $84,212
Family Medicine $84,212
Dr. Arthur Babakhanians, Md, MD
Family Medicine — Payments: $41,750
Family Medicine $41,750
Kecia Smette, Do, DO
Family Medicine — Payments: $40,747
Family Medicine $40,747